- Home
- POLA vs RNAZ Comparison
POLA vs RNAZ Comparison
Compare POLA & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POLA
- RNAZ
- Stock Information
- Founded
- POLA 1979
- RNAZ 2016
- Country
- POLA United States
- RNAZ United States
- Employees
- POLA N/A
- RNAZ N/A
- Industry
- POLA Industrial Machinery/Components
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- POLA Miscellaneous
- RNAZ Health Care
- Exchange
- POLA Nasdaq
- RNAZ Nasdaq
- Market Cap
- POLA 5.6M
- RNAZ 6.1M
- IPO Year
- POLA 2016
- RNAZ 2021
- Fundamental
- Price
- POLA $1.70
- RNAZ $7.97
- Analyst Decision
- POLA
- RNAZ Strong Buy
- Analyst Count
- POLA 0
- RNAZ 1
- Target Price
- POLA N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- POLA 9.0K
- RNAZ 32.8K
- Earning Date
- POLA 08-13-2025
- RNAZ 08-13-2025
- Dividend Yield
- POLA N/A
- RNAZ N/A
- EPS Growth
- POLA N/A
- RNAZ N/A
- EPS
- POLA N/A
- RNAZ N/A
- Revenue
- POLA $13,918,000.00
- RNAZ N/A
- Revenue This Year
- POLA N/A
- RNAZ N/A
- Revenue Next Year
- POLA N/A
- RNAZ N/A
- P/E Ratio
- POLA N/A
- RNAZ N/A
- Revenue Growth
- POLA 8.08
- RNAZ N/A
- 52 Week Low
- POLA $1.65
- RNAZ $6.15
- 52 Week High
- POLA $4.90
- RNAZ $970.20
- Technical
- Relative Strength Index (RSI)
- POLA 42.95
- RNAZ 47.04
- Support Level
- POLA $1.67
- RNAZ $7.32
- Resistance Level
- POLA $1.75
- RNAZ $8.48
- Average True Range (ATR)
- POLA 0.05
- RNAZ 0.58
- MACD
- POLA 0.01
- RNAZ 0.41
- Stochastic Oscillator
- POLA 57.14
- RNAZ 70.77
About POLA Polar Power Inc.
Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Asia, Europe and Middle East, United Kingdom, Other North America, South Africa, and others.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.